These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 32782491)

  • 1. PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers.
    Lee EK; Konstantinopoulos PA
    Ther Adv Med Oncol; 2020; 12():1758835920944116. PubMed ID: 32782491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
    Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
    Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
    [No Abstract]   [Full Text] [Related]  

  • 3. Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer.
    Meng J; Peng J; Feng J; Maurer J; Li X; Li Y; Yao S; Chu R; Pan X; Li J; Zhang T; Liu L; Zhang Q; Yuan Z; Bu H; Song K; Kong B
    J Transl Med; 2021 Oct; 19(1):415. PubMed ID: 34620163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospects for combining immune checkpoint blockade with PARP inhibition.
    Li A; Yi M; Qin S; Chu Q; Luo S; Wu K
    J Hematol Oncol; 2019 Sep; 12(1):98. PubMed ID: 31521196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation.
    Hu X; Zhao M; Bai M; Xue Z; Wang F; Zhu Z; Yu J; Yue J
    Cancer Lett; 2024 Apr; 586():216676. PubMed ID: 38278469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors.
    Wu Z; Cui P; Tao H; Zhang S; Ma J; Liu Z; Wang J; Qian Y; Chen S; Huang Z; Zheng X; Huang D; Hu Y
    Clin Med Insights Oncol; 2021; 15():1179554921996288. PubMed ID: 33737855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer.
    Han Y; Li CW; Hsu JM; Hsu JL; Chan LC; Tan X; He GJ
    Am J Cancer Res; 2019; 9(4):800-815. PubMed ID: 31106005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment.
    Catalano M; Francesco Iannone L; Cosso F; Generali D; Mini E; Roviello G
    Expert Opin Ther Targets; 2022 Nov; 26(11):923-936. PubMed ID: 36519314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer.
    Post CCB; Westermann AM; Bosse T; Creutzberg CL; Kroep JR
    Crit Rev Oncol Hematol; 2020 Aug; 152():102973. PubMed ID: 32497971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of PARP and Immune-Checkpoint Inhibitor Combinations.
    Stewart RA; Pilié PG; Yap TA
    Cancer Res; 2018 Dec; 78(24):6717-6725. PubMed ID: 30498083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
    Henning RJ; Bourgeois M; Harbison RD
    Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition.
    Fenerty KE; Padget M; Wolfson B; Gameiro SR; Su Z; Lee JH; Rabizadeh S; Soon-Shiong P; Hodge JW
    J Immunother Cancer; 2018 Nov; 6(1):133. PubMed ID: 30486888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
    Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
    J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of poly(ADP ribose) polymerase inhibitor-based metronomic therapy on programmed death-ligand 1 and matrix-associated factors in human myeloid cells.
    Ibba SV; Luu HH; Boulares AH
    Am J Transl Res; 2022; 14(12):9025-9030. PubMed ID: 36628210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.
    Higuchi T; Flies DB; Marjon NA; Mantia-Smaldone G; Ronner L; Gimotty PA; Adams SF
    Cancer Immunol Res; 2015 Nov; 3(11):1257-68. PubMed ID: 26138335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP Inhibition Activates STAT3 in Both Tumor and Immune Cells Underlying Therapy Resistance and Immunosuppression In Ovarian Cancer.
    Martincuks A; Song J; Kohut A; Zhang C; Li YJ; Zhao Q; Mak E; Rodriguez-Rodriguez L; Yu H; Cristea M
    Front Oncol; 2021; 11():724104. PubMed ID: 34956861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances and perspectives of PARP inhibitors.
    Yi M; Dong B; Qin S; Chu Q; Wu K; Luo S
    Exp Hematol Oncol; 2019; 8():29. PubMed ID: 31737426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitors in ovarian cancer: where do we stand?
    Leary A; Tan D; Ledermann J
    Ther Adv Med Oncol; 2021; 13():17588359211039899. PubMed ID: 34422119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.